DailyDoctor Archive Specialties Get app
Back to the 31 October 2026 edition

Clinical update · 01 of 05

0/1 h versus 0/3 h troponin pathways: no faster, safety still imprecise

Stay with your validated troponin pathway; moving to 0/1 h is an organisational choice, not a proven gain in speed or safety.

Design
Systematic review and individual participant data meta-analysis of 5 RCTs
Population
110,933 emergency presentations with suspected myocardial infarction
Primary outcome
30-day death or new type 1 MI; ED length of stay; direct discharge
Effect
0.8% vs 1.0%, OR 0.83 (0.45–1.53); stay 314 vs 308 min, ratio 1.03 (0.85–1.25)

This Lancet systematic review obtained individual patient data from all five randomised trials comparing a 0/1 h high-sensitivity troponin pathway with a 0/3 h pathway in suspected myocardial infarction, and harmonised the outcomes. It covered 110,933 presentations.

Death or new type 1 MI within 30 days occurred in 0.8% with 0/1 h and 1.0% with 0/3 h (OR 0.83, 95% CI 0.45–1.53). Median emergency department stay was 314 against 308 minutes, and direct discharge 67.0% against 65.8%; neither difference was significant. Heterogeneity between trials was very high.

The 0/1 h pathway is already in guidelines, and this does not show it is unsafe. What it shows is that shortening the blood-draw interval does not by itself empty a department: the bottleneck is usually the laboratory turnaround, imaging and beds. The safety outcome was also refined after the data were received, which the authors declare.

  • Keep using a validated high-sensitivity troponin pathway, whichever interval your hospital has adopted.
  • Do not expect a switch to 0/1 h alone to shorten emergency stays.
  • Look at laboratory turnaround and discharge processes if flow is the problem.
  • Use the assay-specific cut-offs for the pathway you run, not borrowed thresholds.

Why it matters

It challenges the assumption that a faster blood-draw schedule translates into faster, equally safe care.

Don't overread it

The pooled safety estimate is too imprecise to show either pathway is safer.

The statistics, in plain English

An OR of 0.83 with an interval from 0.45 to 1.53 is compatible with a 55% reduction or a 53% increase in harm — the data cannot tell. I² above 97% for length of stay means the trials disagreed so much that a single average hides very different results in different hospitals.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

guidelinespracticechangingdrugsafety

Tomorrow morning, before your first patient

One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app